Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CH505M5 N197D and CH505 TF mRNA-gp160 Vaccines in Healthy Adults
NCT06557785Phase 1Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2024
- Primary completion
- Mar 2027
- Modality
- Vaccine mRNA, Lipid-based Nanoparticles, mRNA Vaccines
- Countries
- 2
01
Overview
Phase 1, open-label trial of CH505M5 N197D mRNA-gp160 and CH505 TF mRNA-gp160 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of local reactogenicity signs and symptoms at Day 183, Frequency of systemic reactogenicity signs and symptoms at Day 183 and 9 more. Started Nov 2024; status: active, not recruiting.
02
Drugs
CH505M5 N197D mRNA-gp160CH505 TF mRNA-gp160
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06557785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06557785.